Antisense oligodeoxynucleotides against the BZLF1 transcript inhibit induction of productive Epstein-Barr virus replication

Antiviral Research

Volumn 29, Issue 2-3, 1996, Pages 243-260

  Daibata, Masanori ^a   Enzinger, Eva Maria ^a   Monroe, James E ^a   Kilkuskie, Robert E ^b   Field, A Kirk ^b   Mulder, Carel ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b HYBRIDON INC   (United States)

Author keywords

antisense; BZLF1; Epstein Barr virus; latency; phosphorothioates; reactivation

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; GENE PRODUCT; IMMUNOGLOBULIN G ANTIBODY; PHOSPHODIESTER DERIVATIVE; PHOSPHOROTHIOIC ACID DERIVATIVE; UNCLASSIFIED DRUG; VIRUS DNA;

ARTICLE; CELL LINE; CODON; CONCENTRATION RESPONSE; CONTROLLED STUDY; EPSTEIN BARR VIRUS; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; PRIORITY JOURNAL; RNA TRANSLATION; VIRUS INHIBITION; VIRUS REPLICATION;

DNA VIRUSES; HUMAN HERPESVIRUS 4;

EID: 0030007904     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/0166-3542(95)00902-7     Document Type: Article

References (61)

1. Agrawal, S., Ikeuchi, T., Sun, D., Sarin, P.S., Konopka, A., Maizel, J. and Zamecnik, P.C. (1989) Inhibition of human immunodeficiency virus in early infected and chronically infected cells by antisense oligodeoxynucleotides and their phosphorothioate analogues. Proc. Natl. Acad. Sci. USA 86, 7790-7794.
2. Baer, R., Bankier, A.T., Biggin, M.D., Deininger, P.I., Farrell, P.J., Gibson, T.J., Hatfull, G., Hudson, G.S., Satchwell, S.C., Séguin, C., Tuffnell, P.S. and Barrell, E.G. (1984) DNA sequence and expression of the B95-8 Epstein-Barr virus genome. Nature 310, 207-211.
3. Biggin, M., Bodescot, M., Perricaudet, M. and Farrell, P. (1987) Epstein-Barr virus gene expression in P3HR1-superinfected Raji cells. J. Virol. 61, 3120-3132.
4. Chevallier-Greco, A., Manet, E., Chavrier, P., Mosnier, C., Daillie, J. and Sergeant, A. (1986) Both Epstein-Barr virus (EBV)-encoded transacting factors, EB1 and EB2, are required to activate transcription from an EBV early promoter. EMBO J. 5, 3243-3249.
5. Colby, B.M., Shaw, J.E., Elion, G.B. and Pagano, J.S. (1980) Effect of acyclovir {9-(2-hydroxyethoxymethyl)guanine} on Epstein-Barr virus DNA replication. J. Virol. 34, 560-568.
6. Countryman, J. and Miller, G. (1985) Activation of expression of latent Epstein-Barr herpesvirus after gene transfer with a small cloned subfragment of heterogeneous viral DNA. Proc. Natl. Acad. Sci. USA 82, 4085-4089.
7. Countryman, J., Jenson, H., Seibl, R., Wolf, H. and Miller, G. (1987) Polymorphic proteins encoded within BZLF1 of defective and standard Epstein-Barr viruses disrupt latency. J. Virol. 61, 3672-3679.
8. Cowsert, L.M., Fox, M.C., Zon, G. and Mirabelli, C.K. (1993). In vitro evaluation of phosphorothioate oligonucleotides targeted to the E2 mRNA of papillomavirus: potential treatment for genital warts. Antimicrob. Agents Chemother. 37, 171-177.
9. Daibata, M. and Sairenji, T. (1993) Epstein-Barr virus (EBV) replication and expressions of EA-D (BMRFI gene product), virus-specific deoxyribonuclease, and DNA polymerase in EBV-activated Akata cells. Virology 196, 900-904.
10. Daibata, M., Humphreys, R.E., Takada, K. and Sairenji, T. (1990) Activation of latent EBV via anti-IgG-triggered, second messenger pathways in the Burkitt's lymphoma cell line Akata. J. Immunol. 144, 4788-4793.
11. Daibata, M., Mellinghoff, I., Takagi, S., Humphreys, R.E. and Sairenji, T. (1991) Effect of genistein, a tyrosine kinase inhibitor, on latent EBV activation induced by cross-linkage of membrane IgG in Akata B cells. J. Immunol. 147, 292-297.
12. Daibata, M., Humphreys, R.E. and Sairenji, T. (1992) Phosphorylation of the Epstein-Barr virus BZLF1 immediate-early gene product ZEBRA. Virology 188, 916-920.
13. Daibata, M., Speck, S.H., Mulder, C. and Sairenji, T. (1994) Regulation of the BZLF1 promoter of Epstein-Barr virus by second messengers in antiimmunoglobulin-treated B cells. Virology 198, 446-454.
14. Datta, A.K., Colby, B.M., Shaw, J.E. and Pagano, J.S. (1980) Acyclovir inhibition of Epstein-Barr virus replication. Proc. Natl. Acad. Sci. USA 77, 5163-5166.
15. Faggioni, A., Zompetta, C., Grimaldi, S., Barile, G., Frati, L. and Lazdins, J. (1986) Calcium modulation activates Epstein-Barr virus genome in latently infected cells. Science 232, 1554-1556.
16. Fennewald, S.M., Mustain, S., Ojwang, J. and Rando, R.F. (1995) Inhibition of herpes simplex virus in culture by oligonucleotides composed entirely of deoxyguanosine and thymidine. Antiviral Res. 26, 37-54.
17. Flemington, E. and Speck, S.H. (1990) Identification of phorbol ester response elements in the promoter of Epstein-Barr virus putative lytic switch gene BZLF1. J. Virol. 64, 1217-1226.
18. Gardella, T., Medveczky, P., Sairenji, T. and Mulder, C. (1984) Detection of circular and linear herpesvirus DNA molecules in mammalian cells by gel electrophoresis. J. Virol. 50, 248-254.
19. Goodchild, J., Agrawal, S., Civeira, M.P., Sarin, P.S., Sun, D. and Zamecnik, P.C. (1988) Inhibition of human immunodeficiency virus replication by antisense oligodeoxynucleotides. Proc. Natl. Acad. Sci. USA 85, 5507-5511.
20. Hardwick, J.M., Lieberman, P.M. and Hayward, S.D. (1988) A new Epstein-Barr virus transactivator, R, induces expression of a cytoplasmic early antigen. J. Virol. 62, 2274-2284.
21. Harel-Bellan, A., Ferris, D.K., Vinocour, M., Holt, J.T. and Farrar, W.L. (1988) Specific inhibition of c-myc protein biosynthesis using an antisense synthetic deoxy-oligonucleotide in human T lymphocytes. J. Immunol. 140, 2431-2435.
22. Hélène, C. and Toulmé, J.-J. (1990) Specific regulation of gene expression by antisense, sense and antigen nucleic acids. Biochim. Biophys. Acta 1049, 99-125.
23. Hinuma, Y., Konn, M., Yamaguchi, J., Wudarski, D.J., Blakeslee, Jr., J.R. and Grace, Jr., J.T. (1967) Immunofluorescence and herpes-type virus particles in the P3HR-1 Burkitt Lymphoma cell line. J. Virol. 1, 1045-1051.
24. Iwanaga, T. and Ferriola, P.C. (1993) Cellular uptake of phosphorothioate oligodeoxynucleotides is negatively affected by cell density in a transformed rat tracheal epithelial cell line: Implication for antisense approaches. Biochem. Biophys. Res. Commun. 191, 1152-1157.
25. Jenson, H.B. and Miller, G. (1988) Polymorphisms of the region of the Epstein-Barr virus genome which disrupts latency. Virology 165, 549-564.
26. Kenney, S., Kamine, J., Holley-Guthrie, E., Lin, J.-C., Mar, E.-C. and Pagano, J.S. (1989) The Epstein-Barr virus (EBV) BZLF1 immediate-early gene product differentially affects latent versus productive EBV promoters. J. Virol. 63, 1729-1736.
27. Kieff, E. and Liebowitz, D. (1990) Epstein-Barr virus and its replication. In: B.N. Fields and D.M. Knipe (Eds), Virology, 2nd ed, pp. 1889-1920. Raven Press, New York.
28. Leiter, J.M.E., Agrawal, S., Palese, P. and Zamecnik, P.C. (1990) Inhibition of influenza virus replication by phosphorothioate oligodeoxynucleotides. Proc. Natl. Acad. Sci. USA. 87, 3430-3434.
29. Lieberman, P.M., O'Hare, P., Hayward, G.S. and Hayward, S.D. (1986) Promiscuous trans activation of gene expression by an Epstein-Barr virus-encoded early nuclear protein. J. Virol. 60, 140-148.
30. Matsukura, M., Shinozuka, K., Zon, G., Mitsuya, H., Reitz, M., Cohen, J.S. and Broder, S. (1987) Phosphorothioate analogs of oligodeoxynucleotides: inhibition of replication and cytopathic effects of human immunodeficiency virus. Proc. Natl. Acad. Sci. USA 84, 7706-7710.
31. Matsumoto, Alan K., Kopicky-Burd, J., Carter, R.H., Tuvenson, D.A., Tedder, T.F. and Fearon, D.T. (1991) Intersection of the complement and immune systems: A signal transduction complex of the B lymphocyte-containing complement receptor type-2 and CD 19. J. Exp. Med. 173, 55-64.
32. Mellinghoff, I., Daibata, M., Humphreys, R.E., Mulder, C., Takada, K. and Sairenji, T. (1991) Early events in Epstein-Barr virus genome expression after activation: regulation by second messengers of B cell activation. Virology 185, 922-928.
33. Miller, C.L., Longnecker, R. and Kieff, E. (1993) Epstein-Barr virus latent membrane protein 2A blocks calcium mobilization in B lymphocytes. J. Virol. 67, 3087-3094.
34. Miller, G. (1990) Epstein-Barr virus. Biology, pathogenesis, and medical aspects. In: B.N. Fields and D.M. Knipe (Eds), Virology, 2nd Ed, pp. 1921-1958. Raven Press, New York.
35. Ooka, T. and Calender, A. (1980) Effects of arabinofuranosylthymine on Epstein-Barr virus replication. Virology 104, 219-223.
36. Packham, G., Brimmell, M., Cook, D., Sinclair, A.J. and Farrell, P.J. (1993) Strain variation in Epstein-Barr virus immediate early genes. Virology 192, 541-550.
37. Pagano, J.S., Jimenez, G., Sung, N.S., Raab-Traub, N. and Lin, J.-C. (1992) Epstein-Barr viral latency and cell immortalization as targets for antisense oligomers. Ann. NY Acad. Sci. 660, 107-116.
38. Pari, G.S., Field, A.K. and Smith, J.A. (1995) Potent antiviral activity of an antisense oligonucleotide complementary to the intron-exon boundary of human cytomegalovirus genes UL36 and UL37. Antimicrob. Agents Chemother. 39, 1157-1161.
39. Pearson, G.R., Vroman, B., Chase, B., Sculley, T., Hummel, M. and Kieff, E. (1983) Identification of polypeptide components of the Epstein-Barr virus early antigen complex with monoclonal antibodies. J. Virol. 47, 193-201.
40. Roth, G., Curiel T. and Lacy, J. (1994) Epstein-Barr viral nuclear antigen 1 antisense oligodeoxynucleotide inhibits proliferation of Epstein-Barr virus-immortalized B cells. Blood 84, 582-587.
41. Schepers, A., Pich, D., Mankertz, J. and Hammerschmidt, W. (1993) cis-Acting elements in the lytic origin of DNA replication of Epstein-Barr Virus. J. Virol. 67, 4237-4245.
42. Severini, A., Morgan, A.R., Tovell, D.R. and Tyrrell, D.L.J. (1994) Study of the structure of replicative intermediates of HSV-1 DNA by pulsed-field gel electrophoresis. Virology 200, 428-435.
43. Shaw, J.E. (1985) The circular intracellular form of Epstein-Barr virus DNA is amplified by the virus-associated DNA polymerase. J. Virol. 53, 1012-1015.
44. Shimizu, N. and Takada, K. (1993) Analysis of the BZLF1 promoter of Epstein-Barr virus: identification of an anti-immunoglobulin response sequence. J. Virol. 67, 3240-3245.
45. Sinclair, A.J., Brimmell, M., Shanahan, F. and Farrell, P.J. (1991) Pathways of activation of the Epstein-Barr virus productive cycle. J. Virol. 65, 2237-2244.
46. Sista, N.D., Pagano, J.S., Liao, W. and Kenney, S. (1993) Retinoic acid is a negative regulator of the Epstein-Barr virus protein (BZLF1) that mediates disruption of latent infection. Proc. Natl. Acad. Sci. USA 90, 3894-3898.
47. Smith, C.C., Aurelian, L., Reddy, M.P., Miller, P.S. and Ts'o, P.O.P. (1986) Antiviral effect of an oligo(nucleoside methylpbosphonate) complementary to the splice junction of herpes simplex virus type 1 immediate early pre-mRNA 4 and 5. Proc. Natl. Acad. Sci. USA 83, 2787-2791.
48. Smith, J.A. and Pari, G.S. (1995) Expression of human cytomegalovirus UL36 and UL37 genes is required for viral DNA replication. J. Virol. 69, 1925-1931.
49. Stein, C.A. and Cohen, J.S. (1988) Oligodeoxynucleotides as inhibitors of gene expression: a review. Cancer Res. 48, 2659-2668.
50. Stein, C.A., Subasinghe, C., Shinozuka, K. and Cohen, J.S. (1988) Physicochemical properties of phosphorothioate oligodeoxynucleotides. Nucleic Acids Res. 16, 3209-3221.
51. Summers, W.C. and Klein, G. (1976) Inhibition of Epstein-Barr virus DNA synthesis and late gene expression by phosphonoacetic acid. J. Virol. 18, 151-155.
52. Takada, K. and Ono, Y. (1989) Synchronous and sequential activation of latently infected Epstein-Barr virus genomes. J. Virol. 63, 445-449.
53. Takada, K., Shimizu, N., Sakuma, S. and Ono, Y. (1986) trans Activation of the latent Epstein-Barr virus (EBV) genome after transfection of the EBV DNA fragment. J. Virol. 57, 1016-1022.
54. Taylor, N., Countryman, J., Rooney, C., Katz, D. and Miller, G. (1989) Expression of the BZLF1 latency-disrupting gene differs in standard and defective Epstein-Barr viruses. J. Virol. 63, 1721-1728.
55. Tovey, M.G., Lenoir, G. and Begon-Lours, J. (1978) Activation of latent Epstein-Barr virus by antibody to human IgM. Nature 276, 270-272.
56. Wickstrom, E. (1986) Oligodeoxynucleotide stability in subcellular extracts and culture media. J. Biochem. Biophys. Methods 13, 97-102.
57. Yao, G.-Q., Grill, S., Egan, W. and Cheng, Y.-C. (1993) Potent inhibition of Epstein-Barr virus by phosphorothioate oligodeoxynucleotides without sequence specification. Antimicrob. Agents Chemother. 37, 1420-1425.
58. Zalani, S., Holley-Guthrie, E.A., Gutsch, D.E. and Kenney, S.C. (1992) The Epstein-Barr virus immediate-early promoter BRLF1 can be activated by the cellular SP1 transcription factor. J. Virol. 66, 7282-7292.
59. Zamecnik, P.C., Goodchild, J., Taguchi, Y. and Sarin, P.S. (1986) Inhibition of replication and expression of human T-cell lymphotropic virus type III in cultured cells by exogenous synthetic oligonucleotides complementary to viral RNA. Proc. Natl. Acad. USA 83, 4143-4146.
60. Zerial, A., Thuong, N.T. and Hélène, C. (1987) Selective inhibition of the cytopathic effect of type A influenza viruses by oligodeoxynucleotides covalently linked to an intercalating agent. Nucleic Acids Res. 15, 9909-9919.
61. zur Hausen, H., O'Neill, F.J., Freese, U.K. and Hecker, E. (1978) Persisting oncogenic herpesvirus induced by the tumor promoter TPA. Nature 272, 373-375.